Other EGFR mAbs, such as zalutumumab, panitumumab, nimotuzumab, have been tested in numerous clinical trials and in different settings; however, none of them have been approved for use in HNSCC in the UK [16]. Here, EGFR is linked to head and neck squamous cell carcinoma.